Reducing pharmaceutical reimbursement price risk to lower national health expenditures without lowering R&D incentives
Bibliographic Data
| ID | 13122364 |
|---|---|
| Authors | Hiroshi Nakamura (0000-0001-7699-9840, Keio University), Naohiko Wakutsu (0000-0002-7925-9669, Nagoya City University, corresponding author) |
| Year | 2018 |
| Volume | 13 |
| Issue | 1 |
| Pages | 75-88 |
| Publication date | 2018-12-03 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Economic Policy Studies (JOURNAL) |
| Journal identifiers | ISSN: 2524-4892 • E-ISSN: 1881-4387 |
| Publisher | Springer Science+Business Media (PUBLISHER • DE) |
| DOI | 10.1007/s42495-018-0002-7 |
| OpenAlex | W2902439431 |
| Language | EN |
| References cited | 21 |
Actuarial science · Business · Economics · Expected utility hypothesis · Financial economics · Health care · Incentive · Microeconomics · Pharmaceutical industry · Public economics · Reimbursement · Risk aversion (psychology · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Pharmacology
| Highly cited | No |
|---|